Skip to main content

Inpharmatica Wins Japanese Pharma Customer for Predictive ADME Software

NEW YORK, Oct. 11 (GenomeWeb News) - Inpharmatica has licensed its Admensa Interactive predictive ADME software to Japanese pharmaceutical company Mochida, the company said today.

 

This is the second Japanese company that has licensed Admensa Interactive, and the sixth overall since Inpharmatica launched the product in February.

 

The agreement was secured in conjunction with PharmaDesign, Inpharmatica's sales and marketing partner in Japan, Inpharmatica said.

 

Financial details of the agreement were not disclosed.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.